Q-omics provides the consensus-scored DLEU2L profile across patient tissues and cancer cell-line models. DLEU2L expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, DLEU2L is differentially expressed in 6, with the highest sampling consensus in CHOL. Additionally, DLEU2L protein abundance shows 21,066 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KICH, CHOL, and LUAD as cancer lineages where DLEU2L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DLEU2L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DLEU2L survival associations across molecular data types. DLEU2L RNA expression shows survival associations in the most cancer types (22), followed by mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DLEU2L RNA expression–survival associations across cancer types. High DLEU2L expression shows unfavorable associations in KICH, LGG and LIHC, but favorable associations in READ, UCS and HNSC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for DLEU2L RNA expression.
This table summarizes DLEU2L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 4. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DLEU2L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DLEU2L shows lower tumor expression in UCEC and higher tumor expression in CHOL, BLCA, LIHC, KIRC and STAD. The CHOL box plot shows higher DLEU2L RNA expression in tumor versus normal tissue (log2 FC = +0.517, t-test p < 0.001).
This table shows molecular features associated with DLEU2L in patient tissues and cancer cell lines. In patient samples, DLEU2L shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
